Eupraxia Pharmaceuticals Inc Market Cap ($371.51 Million)
Market Cap & Net Worth: Eupraxia Pharmaceuticals Inc (EPRX)
Eupraxia Pharmaceuticals Inc market cap. Eupraxia Pharmaceuticals Inc (TO:EPRX) has a market capitalization of $371.51 Million (CA$513.57 Million) as of October 31, 2026. Listed on the TO stock exchange, this Canada-based company holds position #13565 globally and #404 in its home market, demonstrating a -6.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eupraxia Pharmaceuticals Inc's stock price CA$10.14 by its total outstanding shares 50648331 (50.65 Million).
Eupraxia Pharmaceuticals Inc Market Cap History (2021–2026)
Eupraxia Pharmaceuticals Inc market cap history from 2021 to 2026. Data shows growth from $89.76 Million to $371.51 Million (7.06% CAGR). Check today's stock price for Eupraxia Pharmaceuticals Inc for real-time trading data and today's change.
Eupraxia Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eupraxia Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Eupraxia Pharmaceuticals Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EPRX by Market Capitalization
Companies near Eupraxia Pharmaceuticals Inc in the global market cap rankings as of October 31, 2026. See net asset quality index of Eupraxia Pharmaceuticals Inc to understand what proportion of total assets are financed by equity.
Key companies related to Eupraxia Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Eupraxia Pharmaceuticals Inc (2021–2026)
Market capitalization of Eupraxia Pharmaceuticals Inc from 2021 to today. Between 2021 and today, Eupraxia Pharmaceuticals Inc's market cap moved from $89.76 Million to $ 371.51 Million, with a yearly change of 7.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$371.51 Million | -1.74% |
| 2025 | CA$378.11 Million | +128.82% |
| 2024 | CA$165.24 Million | -16.01% |
| 2023 | CA$196.75 Million | +47.12% |
| 2022 | CA$133.73 Million | +48.98% |
| 2021 | CA$89.76 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Eupraxia Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $371.51 Million USD |
| MoneyControl | $371.51 Million USD |
| MarketWatch | $371.51 Million USD |
| marketcap.company | $371.51 Million USD |
| Reuters | $371.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more